Advancements in chemotherapy and immunotherapy have improved multiple myeloma survival rates, with 5-year relative survival increasing from 37.7% to 60.3% between 2000-2004 and 2015-2019. Treatment ...

(RTTNews) - Johnson & Johnson (JNJ) shared new findings at the 2025 ASCO Annual Meeting from two Phase 3 studies, PERSEUS and CEPHEUS, highlighting the long-term benefits of a DARZALEX FASPRO ...

Multiple myeloma is the second most common blood cancer in the United States. Thirty to 50 percent of multiple myeloma patients have extra copies of the gene that encodes the enzyme ADAR1. Using a ...

A Japanese government survey shows the five-year survival rates for patients aged 15 or older with pancreatic cancer, ...

Success is no longer just about prolonging survival, but about enabling patients to live well after cancer, with fewer ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...

Staging is when a system is used to identify and describe how far a cancer has spread in your body. Knowing the stage of your multiple myeloma helps your physicians predict which treatments are most ...

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.